Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Capecitabine plus oral vinorelbine standard schedule versus metronomic schedule in HER2-negative metastatic breast cancer
2011-003564-72Phase 2Completed
- Sponsor
- Aarhus University Hospital
- Start
- Jan 2012
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of capecitabine and vinorelbine in breast cancer (2 arms), sponsored by Aarhus University Hospital. Primary endpoint: Response rate. Started Jan 2012; status: completed.
02
Drugs
capecitabinevinorelbine
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2011-003564-72.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-003564-72.